These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
802 related articles for article (PubMed ID: 17461850)
1. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study. Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850 [TBL] [Abstract][Full Text] [Related]
2. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718 [TBL] [Abstract][Full Text] [Related]
3. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B; J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902 [TBL] [Abstract][Full Text] [Related]
4. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. Valer L; de Mendoza C; Soriano V J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964 [TBL] [Abstract][Full Text] [Related]
5. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K; HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686 [TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618 [TBL] [Abstract][Full Text] [Related]
8. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J; Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443 [TBL] [Abstract][Full Text] [Related]
10. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863 [TBL] [Abstract][Full Text] [Related]
11. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM; Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093 [TBL] [Abstract][Full Text] [Related]
12. Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children. Larru B; de Mendoza C; Bellón JM; de José MI; Mellado MJ; Soriano V; Muñoz-Fernandez MA; Ramos JT BMC Infect Dis; 2007 Jun; 7():55. PubMed ID: 17559687 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B; Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750 [TBL] [Abstract][Full Text] [Related]
14. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy. Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir. Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564 [TBL] [Abstract][Full Text] [Related]
16. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J; Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099 [TBL] [Abstract][Full Text] [Related]
19. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen. Castagna A; Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Hoetelmans R; Nauwelaers D; Lazzarin A Antivir Ther; 2004 Aug; 9(4):537-43. PubMed ID: 15456085 [TBL] [Abstract][Full Text] [Related]
20. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. Hill A; Sawyer W HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]